NEW YORK (GenomeWeb News) - Millenium Pharmaceuticals said Tuesday it has identified a genomic biomarker during Phase II trials of a cardiovascular disease drug.

 

The company said it has found that 11.3 percent of patients treated with its MLN1202 monoclonal antibody had a reduction of C-reactive protein (CRP), and that CRP reductions were more likely in patients with a SNP that was identified in 53 percent of the study population.